Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Royal Philips (NYSE: PHG) announced the launch of the Duo Venous Stent System after obtaining premarket approval from the FDA. The system, designed to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency (CVI), was first used outside clinical trials on June 12, 2024, at Sanger Heart & Vascular Institute, Atrium Health. The Duo Venous Stent System includes two stents, Duo Hybrid and Duo Extend, engineered to address the complexities of venous anatomy and obstructions.
The VIVID study, a global clinical trial, supported FDA approval by demonstrating a 90.2% primary patency rate and 98.7% safety rate at 12 months, exceeding performance targets. Improved quality of life and venous functional assessments were noted in patients. Philips' launch aims to enhance clinical outcomes and quality of life for CVI patients globally.
Philips (NYSE: PHG) has unveiled its next-generation AI-enabled cardiovascular ultrasound platform, integrating advanced AI applications into its EPIQ CVx and Affiniti CVx ultrasound systems. These innovations, cleared by the FDA, include the industry's first automated tool for segmental wall motion scoring, enhancing the detection of coronary artery disease and cardio-oncology issues. Additionally, Philips introduces the first fully automated 3D quantification of mitral regurgitation volumes, aiding in consistent and efficient analysis for heart valve disease patients. These advancements aim to speed up cardiac ultrasound analysis, improve diagnostic accuracy, and reduce the burden on echocardiography labs. The new AI tools, co-developed with DiA Imaging Analysis and other technology partners including NVIDIA, promise to enhance clinical decision-making, reduce re-scans, and shorten recovery times. Philips will present these innovations at the ASE2024 annual meeting.
Philips announced its 1,111th installation of the BlueSeal 1.5T magnet, marking a milestone in helium-free MRI operations. This installation took place at the Vida Imaging & Breast Center in Puerto Rico. Since 2018, Philips has led the market in helium-free MRIs, saving approximately 1.9 million liters of liquid helium. The BlueSeal magnet technology allows for controlled shutdowns and re-energizing, important for areas prone to natural disasters like Puerto Rico. This system only requires 7 liters of helium during manufacturing, unlike traditional MRIs that need up to 1700 liters. The technology is AI-enabled and lighter by 900kg compared to conventional systems, making it installable in various challenging locations including mobile units.
Royal Philips has successfully priced its offering of EUR 700 million fixed rate notes, set to mature in 2032, under its European Medium Term Note (EMTN) program.
The notes were priced at 98.257% with a 3.75% coupon, resulting in a yield of 4.009%.
The issue, which was over two times oversubscribed, aims to be debt-neutral as it will be used to repay existing debt due in 2024 and 2025.
Philips holds a BBB+ rating from Standard & Poor's and Fitch, and a Baa1 rating from Moody's.
The settlement and issue of the notes are scheduled for May 31, 2024, and the notes will be listed on the Luxembourg Stock Exchange.
This offering is not registered under the U.S. Securities Act and is not intended for retail investors in the EEA or UK.
Philips has launched its wearable ePatch and AI-driven Cardiologs analytics platform in 14 hospitals across Spain.
The ePatch, a 14-day continuous Holter monitor, helps detect life-threatening heart arrhythmias like atrial fibrillation (AF).
Dr. Jorge Pagola of University Hospital Vall d'Hebron highlighted its benefits, including enhanced patient comfort and reduced hospital stays, which saved approximately €28,800 in 2023.
More than 1500 patients are currently being monitored using ePatch devices, reducing wait times and improving care access.
Studies show the ePatch detects 2.5 times more arrhythmias over 14 days compared to traditional 24-hour Holter monitors.
Philips Foundation released its 2023 Annual Report, showcasing efforts to improve healthcare access for over 28 million people in underserved communities, aligning with its 2030 goal to reach 100 million annually.
The report highlights 17 new initiatives and 4 new investments in health tech enterprises leveraging Philips' expertise.
Key focus areas include mother and child health, non-communicable disease detection, and acute care services, emphasizing early screening and diagnosis.
Philips Foundation supports social enterprises, with 13 projects backed in 2023, creating an ecosystem to boost growth and impact.
Chair of the Board, Marnix van Ginneken, affirmed the foundation's commitment to sustainable healthcare development and collaboration with various partners.
Philips showcased the benefits of its AI-powered cardiac monitoring solutions at the Heart Rhythm Annual Meeting. Three studies highlighted how Philips' Mobile Cardiac Outpatient Telemetry (MCOT) wearable ECG and AI models improve diagnosis, reduce readmissions, and lower costs. A study published in The Journal of Comparative Effectiveness Research found that MCOT reduces readmissions in stroke patients (30.2% vs. 35.4% with ILR), lowers costs by USD 27,429 over 18 months, and increases survival rates.
Additional research demonstrated that AI-driven ECG technology aids in identifying potentially life-threatening arrhythmias and accurately diagnosing syncope causes. Another study revealed that urgent notifications from MCOT led to timely follow-ups and procedural interventions, enhancing patient outcomes.
Philips will also educate on managing cardiac implantable electronic device (CIED) infections, offering comprehensive lead management solutions.
Royal Philips (NYSE: PHG) announced the exchange ratio for its 2023 dividend, set at 1 new common share for every 29.2684 existing shares. This ratio, based on a volume-weighted average price of EUR 24.8481 on Euronext Amsterdam, equates to a gross dividend of approximately EUR 0.85 per share. Philips plans to issue a total of 30,860,582 new common shares. Distribution and settlement are scheduled for May 16, 2024. Furthermore, Philips will cancel 4,437,164 shares acquired under its EUR 1.5 billion share repurchase program, reducing the total share count to 939,939,384.
Royal Philips announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2024, including key appointments and resolutions. Feike Sijbesma and Peter Löscher were re-appointed to the Supervisory Board, Benoît Ribadeau-Dumas was appointed as a new member, and Charlotte Hanneman was appointed to the Board of Management as Chief Financial Officer. The resolutions included the adoption of the financial statements for 2023, a dividend of EUR 0.85 per common share, and positive advisory votes on the Remuneration Report 2023. The AGM also approved the Remuneration Policy for the Board of Management and the Supervisory Board, authorized the issuance and acquisition of shares, and cancelled shares.
Philips Avent partners with March of Dimes for the It Starts With Mom initiative, supporting new moms with resources for health and well-being. The partnership aims to benefit local communities, NICU families, and maternity care deserts. A recent survey showed the need for support for new moms, and Philips Avent's Share the Care campaign advocates for community involvement in baby care to allow moms more time for self-care. The initiative highlights the importance of maternal health, with various programs and partnerships focusing on supporting families globally.